ProQR (PRQR) Reports Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients; Plans to Start a Phase 2/3 Pivotal Trial
Tweet Send to a Friend
ProQR Therapeutics N.V. (NASDAQ: PRQR) today announced results from a planned interim analysis of its Phase 1/2 trial of QR-110 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
